These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28556555)

  • 1. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.
    Mohammad S; Clowse MEB; Eudy AM; Criscione-Schreiber LG
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):481-485. PubMed ID: 28556555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Hydroxychloroquine use and Hemolytic Anemia in Patients With Low Levels of Glucose-6-Phosphate Dehydrogenase.
    Ramirez de Oleo IE; Mejia Saldarriaga M; Johnson BK
    J Clin Rheumatol; 2022 Jan; 28(1):e23-e25. PubMed ID: 32956151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
    Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
    Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.
    Onori ME; Ricciardi Tenore C; Urbani A; Minucci A
    Mol Biol Rep; 2021 Mar; 48(3):2973-2978. PubMed ID: 33620659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model.
    Zuchelkowski BE; Wang L; Gingras S; Xu Q; Yang M; Triulzi D; Page GP; Gordeuk VR; Kim-Shapiro DB; Lee JS; Gladwin MT
    PLoS One; 2020; 15(10):e0240266. PubMed ID: 33007039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E; Yokogawa N; Shimada K; Sugii S
    Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
    Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
    Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
    Leroux M; Desveaux C; Parcevaux M; Julliac B; Gouyon JB; Dallay D; Pellegrin JL; Boukerrou M; Blanco P; Lazaro E
    Lupus; 2015 Nov; 24(13):1384-91. PubMed ID: 26082465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
    Fairley JL; Nikpour M; Mack HG; Brosnan M; Saracino AM; Pellegrini M; Wicks IP
    Intern Med J; 2023 Mar; 53(3):311-317. PubMed ID: 35969110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
    Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
    Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus.
    Martín-Iglesias D; Artaraz J; Fonollosa A; Ugarte A; Arteagabeitia A; Ruiz-Irastorza G
    Lupus; 2019 Apr; 28(4):555-559. PubMed ID: 30755141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.
    Walbi IA; Albarqi HA; Alghanim NS; Albadi MA; Al Maimouni HM; Alkahtani SA; Alshabi AM; Alali AS; Alqahtani F; Al-Najjar AH; Hazzazi MA; Alanazi DS; Sabei AA; Alsaweed OS; Alajra RK; Alqhtani H
    J Int Med Res; 2022 Apr; 50(4):3000605221090363. PubMed ID: 35387504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.